Finally, we compared the effects of AZ628 and Dabrafenib, both as single agents and in combination with Trametinib (MEK inhibitor), in a human NSCLC cell line (H1666) harboring a kinase-impaired BRAF mutation (G466V). Here, MAP2K7 is linked to non-small cell lung carcinoma.